Fundraising FoxBasilard BioTech
4 known investors
Find your way into Basilard BioTech
Sign up to see every warm intro you have to Basilard BioTech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Basilard BioTech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.
Investors · 4
How we know: GENERAL INCEPTION's portfolio page · Not right? Tell us
How we know: funding news · basilardbiotech.com · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountpre-seedMar 2020
Vertical Venture Partners (VVP)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Basilard BioTech do?
- Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.
- Who are Basilard BioTech's investors?
- Basilard BioTech's investors include Band of Angels, GENERAL INCEPTION, Paladin Capital Group, Vertical Venture Partners.